Search for: "In re N.D. & M.D" Results 101 - 120 of 196
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
23 Jun 2014, 12:57 pm by Schachtman
Michal Freedman, and Leon Gordis, Reference Guide on Epidemiology 549, 617 & n.211, in Reference Manual on Scientific Evidence (3ed ed. 2011)[RMSE]. 2. [read post]
20 Oct 2010, 1:20 pm by Bexis
The Supreme Court acepted an appeal in Bruesewitz, that appeal is pending at No. 09-152.In re Aredia & Zometa Products Liability Litigation, 2009 WL 2497229 (M.D. [read post]
27 Mar 2018, 5:02 pm by Wolfgang Demino
New York.February 23, 2018.Natalie Jean-Baptiste, Plaintiff, pro se.NCO Financial Services Inc & Access Group Inc., Defendants, represented by Michael G. [read post]
3 May 2016, 5:08 pm by Kevin LaCroix
In this guest post, Stephen O’Donnell of the Steptoe & Johnson law firm takes a look at two particular standard features of the cyber liability insurance policies, the retroactive date and policy inception date exclusions, and the potential for these exclusions to preclude coverage for the very kind of exposures that are the reasons most purchasers buy the insurance. [read post]
27 Jul 2012, 12:40 pm by Bexis
”  In re Epogen & Aranesp Off-Label Marketing & Sales Practices Litigation, 590 F. [read post]
18 Jan 2013, 2:06 pm by Bexis
  We have to think that asbestos plaintiffs are going to have a field day with Weeks – more, perhaps, than even generic plaintiffs, since the learned intermediary rule still applies to prescription drug cases.Anyway, we could go through each of these policy considerations at length, but we’re not going to. [read post]
19 Sep 2013, 9:53 am by Bexis
., 712 F.3d 60 (1st Cir. 2013) – all of which also travel under the heading, In re Neurontin Marketing and Sales Practices Litigation. [read post]
5 Apr 2012, 11:54 am by Bexis
March 28, 2012) (including fraudulent concealment); In re Darvocet, Darvon & Propoxyphene Products Liability Litigation, 2012 WL 718618, at *5 (E.D. [read post]
28 Dec 2012, 1:57 pm by Bexis
McNeil Consumer & Specialty Pharmaceuticals, 672 F.3d 372 (5th Cir. 2012). [read post]